Follow-up confirms apalutamide survival benefits in some men with prostate cancer

Reuters Health - 16/09/2020 - Apalutamide markedly extends overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), according to a final analysis of data from the phase-3 SPARTAN study. "With data presented herein, all primary and secondary study end points of SPARTAN were met; findings demonstrate the value of apalutamide as a treatment option for nonmetastatic castration-resistant prostate cancer," Dr. Matthew R. Smith of Massachusetts General Hospital Cancer Center and Harvard Medical School in Boston and colleagues conclude in European Urology. Patients with nmCPRC have increasing prostate-specific antigen (PSA) levels despite being on androgen-deprivation therapy (ADT), without metastases, Dr. Smith and his team explain in their report. They will "invariably progress to metastatic disease" without additional treatment, they add. In the SPARTAN study 1,207 nmCPRC patients with PSA doubling times of 10 months or less o...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 16 September, 202030 September, 2020